Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

Stopped EMA withdrew the marketing Authorisation at the request of AGC Biologics S.p.A (formerly MolMed S.p.A), which decided to permanently discontinue the marketing of the product for commercial reasons

Conditions

• Acute Leukemia (Category)

Interventions

• GENETIC: HSV-Tk
• OTHER: T-cell depleted or T-cell replete strategies

Sponsor

AGC Biologics S.p.A.